- Home
- IMMX
IMMX
Immix Biopharma Inc.
as 02-21-2025 4:00pm EST
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 55.3M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 84.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $3.80 | Next Earning Date: | 03-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 600.00% |
Stock Insider Trading Activity of Immix Biopharma Inc. (IMMX)
Latest Immix Biopharma Inc. News
IMMX Breaking Stock News: Dive into IMMX Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy
GlobeNewswire
12 days ago
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
Simply Wall St.
17 days ago
Several Insiders Invested In Immix Biopharma Flagging Positive News
MT Newswires
a month ago
Immix Biopharma Says Patients Dosed in AL Amyloidosis Trial Safety Run-in Successfully Complete Safety Evaluation
GlobeNewswire
a month ago
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
MT Newswires
2 months ago
Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis
GlobeNewswire
2 months ago
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
GlobeNewswire
2 months ago
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Compare IMMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMMX Immix Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.